Eptifibatide Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 2 mg/mL
Reference Brands: Integrilin (USA)
Category:
Heart Disorder
Eptifibatide is available in Injection
and strengths such as 2 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Eptifibatide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Eptifibatide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Eptifibatide is a potent intravenous antiplatelet agent belonging to the glycoprotein IIb/IIIa inhibitor class, widely used to reduce ischemic cardiac events in high-risk cardiovascular patients. It is FDA-approved for the medical management of unstable angina and non-ST elevation myocardial infarction (NSTEMI), as well as for patients undergoing percutaneous coronary intervention (PCI), including intracoronary stent placement. Clinical evidence from the IMPACT-II trial demonstrated that eptifibatide, when used in combination with heparin and aspirin, significantly reduces ischemic complications following PCI, particularly in patients with unstable angina.
Eptifibatide is marketed under the brand name Integrilin and was developed by Millennium Pharmaceuticals, with co-promotion by Schering-Plough/Essex. Structurally, it is a synthetic cyclic heptapeptide derived from a disintegrin protein originally identified in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Pharmacologically, it acts as a reversible arginine-glycine-aspartate (RGD) mimetic that inhibits platelet aggregation by blocking fibrinogen binding to activated glycoprotein IIb/IIIa receptors on platelets. Eptifibatide has a rapid onset of action and a short half-life, making it suitable for controlled use in acute cardiac care settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing